Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
To assess the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for treatment of nonalcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH), we performed a systematic review and meta-analysis of randomized controlled trials (RCTs). Three large electronic databases were system...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Metabolites |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-1989/11/2/73 |
| _version_ | 1797406911824396288 |
|---|---|
| author | Alessandro Mantovani Graziana Petracca Giorgia Beatrice Alessandro Csermely Amedeo Lonardo Giovanni Targher |
| author_facet | Alessandro Mantovani Graziana Petracca Giorgia Beatrice Alessandro Csermely Amedeo Lonardo Giovanni Targher |
| author_sort | Alessandro Mantovani |
| collection | DOAJ |
| description | To assess the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for treatment of nonalcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH), we performed a systematic review and meta-analysis of randomized controlled trials (RCTs). Three large electronic databases were systematically searched (up to 15 December 2020) to identify placebo-controlled or active-controlled RCTs using different GLP-1 RAs. We included eleven placebo-controlled or active-controlled phase-2 RCTs (involving a total of 936 middle-aged individuals) that used liraglutide (<i>n</i> = 6 RCTs), exenatide (<i>n</i> = 3 RCTs), dulaglutide (<i>n</i> = 1 RCT) or semaglutide (<i>n</i> = 1 RCT) to specifically treat NAFLD or NASH, detected by liver biopsy (<i>n</i> = 2 RCTs) or imaging techniques (<i>n</i> = 9 RCTs). Compared to placebo or reference therapy, treatment with GLP-1 RAs for a median of 26 weeks was associated with significant reductions in the absolute percentage of liver fat content on magnetic resonance-based techniques (pooled weighted mean difference: −3.92%, 95% confidence intervals (CI) −6.27% to −1.56%) and serum liver enzyme levels, as well as with greater histological resolution of NASH without worsening of liver fibrosis (pooled random-effects odds ratio 4.06, 95% CI 2.52–6.55; for liraglutide and semaglutide only). In conclusion, treatment with GLP-1 RAs (mostly liraglutide and semaglutide) is a promising treatment option for NAFLD or NASH that warrants further investigation. |
| first_indexed | 2024-03-09T03:33:35Z |
| format | Article |
| id | doaj.art-7de0f2a32737421699993bab860af212 |
| institution | Directory Open Access Journal |
| issn | 2218-1989 |
| language | English |
| last_indexed | 2024-03-09T03:33:35Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Metabolites |
| spelling | doaj.art-7de0f2a32737421699993bab860af2122023-12-03T14:51:32ZengMDPI AGMetabolites2218-19892021-01-011127310.3390/metabo11020073Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled TrialsAlessandro Mantovani0Graziana Petracca1Giorgia Beatrice2Alessandro Csermely3Amedeo Lonardo4Giovanni Targher5Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Verona, 37126 Verona, ItalySection of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Verona, 37126 Verona, ItalySection of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Verona, 37126 Verona, ItalySection of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Verona, 37126 Verona, ItalyInternal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, ItalySection of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Verona, 37126 Verona, ItalyTo assess the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for treatment of nonalcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH), we performed a systematic review and meta-analysis of randomized controlled trials (RCTs). Three large electronic databases were systematically searched (up to 15 December 2020) to identify placebo-controlled or active-controlled RCTs using different GLP-1 RAs. We included eleven placebo-controlled or active-controlled phase-2 RCTs (involving a total of 936 middle-aged individuals) that used liraglutide (<i>n</i> = 6 RCTs), exenatide (<i>n</i> = 3 RCTs), dulaglutide (<i>n</i> = 1 RCT) or semaglutide (<i>n</i> = 1 RCT) to specifically treat NAFLD or NASH, detected by liver biopsy (<i>n</i> = 2 RCTs) or imaging techniques (<i>n</i> = 9 RCTs). Compared to placebo or reference therapy, treatment with GLP-1 RAs for a median of 26 weeks was associated with significant reductions in the absolute percentage of liver fat content on magnetic resonance-based techniques (pooled weighted mean difference: −3.92%, 95% confidence intervals (CI) −6.27% to −1.56%) and serum liver enzyme levels, as well as with greater histological resolution of NASH without worsening of liver fibrosis (pooled random-effects odds ratio 4.06, 95% CI 2.52–6.55; for liraglutide and semaglutide only). In conclusion, treatment with GLP-1 RAs (mostly liraglutide and semaglutide) is a promising treatment option for NAFLD or NASH that warrants further investigation.https://www.mdpi.com/2218-1989/11/2/73GLP-1 receptor agonistsexenatideliraglutidesemaglutidedulaglutidenonalcoholic fatty liver disease |
| spellingShingle | Alessandro Mantovani Graziana Petracca Giorgia Beatrice Alessandro Csermely Amedeo Lonardo Giovanni Targher Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials Metabolites GLP-1 receptor agonists exenatide liraglutide semaglutide dulaglutide nonalcoholic fatty liver disease |
| title | Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials |
| title_full | Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials |
| title_fullStr | Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials |
| title_full_unstemmed | Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials |
| title_short | Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials |
| title_sort | glucagon like peptide 1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis an updated meta analysis of randomized controlled trials |
| topic | GLP-1 receptor agonists exenatide liraglutide semaglutide dulaglutide nonalcoholic fatty liver disease |
| url | https://www.mdpi.com/2218-1989/11/2/73 |
| work_keys_str_mv | AT alessandromantovani glucagonlikepeptide1receptoragonistsfortreatmentofnonalcoholicfattyliverdiseaseandnonalcoholicsteatohepatitisanupdatedmetaanalysisofrandomizedcontrolledtrials AT grazianapetracca glucagonlikepeptide1receptoragonistsfortreatmentofnonalcoholicfattyliverdiseaseandnonalcoholicsteatohepatitisanupdatedmetaanalysisofrandomizedcontrolledtrials AT giorgiabeatrice glucagonlikepeptide1receptoragonistsfortreatmentofnonalcoholicfattyliverdiseaseandnonalcoholicsteatohepatitisanupdatedmetaanalysisofrandomizedcontrolledtrials AT alessandrocsermely glucagonlikepeptide1receptoragonistsfortreatmentofnonalcoholicfattyliverdiseaseandnonalcoholicsteatohepatitisanupdatedmetaanalysisofrandomizedcontrolledtrials AT amedeolonardo glucagonlikepeptide1receptoragonistsfortreatmentofnonalcoholicfattyliverdiseaseandnonalcoholicsteatohepatitisanupdatedmetaanalysisofrandomizedcontrolledtrials AT giovannitargher glucagonlikepeptide1receptoragonistsfortreatmentofnonalcoholicfattyliverdiseaseandnonalcoholicsteatohepatitisanupdatedmetaanalysisofrandomizedcontrolledtrials |